Waters Acquires Halo Labs to Bolster Biological Analysis Portfolio

Waters Corporation has acquired Halo Labs, an innovative provider of specialized imaging technologies for the detection and analysis of disruptive materials in therapeutic products. This acquisition strengthens Waters' offerings in biological analysis, integrating Halo Labs' Aura™ platform's novel particle analysis technology with its existing product lines, such as Wyatt Technology. The move is expected to enhance Waters' leadership in analytical technologies for new biopharmaceutical therapies, including emerging areas like CAR-T cell therapy. Halo Labs will benefit from Waters' resources, potentially accelerating their platform's reach and therapeutic production improvements while maintaining a focus on drug quality and safety. The acquisition is projected to have minimal impact on Waters' financials over the next year.